Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Klaus Mohrs is active.

Publication


Featured researches published by Klaus Mohrs.


European Journal of Pharmacology | 1994

Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005

Phillip J. Gardiner; Nigel J. Cuthbert; Hilary P Dr Francis; Mary F. Fitzgerald; Angela M. Thompson; Tracey G. Carpenter; Umesh P. Patel; Benjamin B. Newton; Klaus Mohrs; Reiner Muller-Peddinghaus; William A. Taylor

BAY x1005 ((R)-2-[4-quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid), an inhibitor of leukotriene synthesis, was evaluated, both in vitro and in vivo, for inhibition of antigen-induced airway contraction in the sensitised guinea-pig. Antigen (ovalbumin 0.001-10 micrograms/ml) challenge of tracheae in the presence of pyrilamine and indomethacin induced contractile responses which were inhibited by BAY x1005 with an IC50 value of 0.36 (0.2-0.8) microM. Using the same test system BAY x1005 (1 microM), ICI D2138 (0.3 microM) or AA 861 (1 microM) had similar inhibitory activities, whereas MK 886, MK 591, and Zileuton (A64077) all tested at 1 microM and REV 5901 (10 microM) had no significant effect. Using tracheae from non-sensitised (control) guinea-pigs the calcium ionophore A23187 (1 microM) induced a maximal contraction which was significantly inhibited by BAY x1005 at 1 microM, whereas MK 886 was only active at 3 microM. BAY x1005 tested at 10 microM and 3 microM had no effect against leukotriene D4- or KCl-induced contractions of guinea-pig tracheae respectively. In the anaesthetised ovalbumin sensitised guinea-pig BAY x1005 caused a dose-related inhibition of ovalbumin-induced bronchoconstriction, with approximate ID50 values of 0.85 mg/kg i.v. and 6.3 mg/kg p.o. In the same model MK 886, MK 591, AA 861 and ICI D2138 each given at 10 mg/kg p.o. had no significant inhibitory activity against antigen challenge. Six hours after administration BAY x1005 (10 mg/kg p.o.) was still effective against the antigen-induced response.(ABSTRACT TRUNCATED AT 250 WORDS)


Archive | 1989

Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic-acid derivatives

Klaus Mohrs; Siegfried Raddatz; Elisabeth Perzborn; Romanis Fruchtmann; Christian Kohlsdorfer; Reiner Muller-Peddinghaus; Pia Theisen


Archive | 1989

Substituted 4-(quinolin-2-yl-methoxy)phenyl-acetic acid derivatives and anti-allergic use thereof

Klaus Mohrs; Siegfried Raddatz; Elisabeth Perzborn; Romanis Fruchtmann; Christian Kohlsdorfer; Reiner Muller-Peddinghaus; Pia Theisen


Archive | 1987

Substituted phenyl-sulphon amides

Klaus Mohrs; Elisabeth Perzborn; Friedel Seuter; Romanis Dipl.-Biologin Fruchtmann; Christian Kohlsdorfer


Archive | 1992

Heterocyclic substituted phenylacetic-acid derivatives, process for their preparation and their pharmaceutical application

Ulrich Dr. Müller; Klaus Mohrs; Jürgen Dr. Dressel; Rudolf Dr. Hanko; Walter Dr. Hübsch; Michael Matzke; Ulrich Niewohner; Siegfried Raddatz; Thomas Dr. Krämer; Matthias Dr. Müller-Gliemann; Hans-Peter Dr. Bellemann; Martin Dr. Beuck; Stanislav Kazda; Stefan Wohlfeil


Archive | 1990

Substituted quinol-2-yl-methoxy-phenylacetic acid derivatives

Klaus Mohrs; Siegfried Raddatz; Romanis Fruchtmann; Christian Kohlsdorfer; Reiner Muller-Peddinghaus; Pia Theisen-Popp


Archive | 1989

Optionally alpha-substituted 4-(quinolin-2-yl-methoxy)phenyl acetic acids and esters

Klaus Mohrs; Siegfried Raddatz; Romanis Fruchtmann; Christian Kohlsdorfer; Reiner Muller-Peddinghaus


Archive | 1989

α-substituted 4-(quinolin-2-yl-methoxy)phenylacetic acids and esters and lipoxygenase inhibition therewith

Klaus Mohrs; Siegfried Raddatz; Romanis Fruchtmann; Christian Kohlsdorfer; Reiner Muller-Peddinghaus


Archive | 1991

Antiflammatory quinolin methoxy phenylsulphonamides

Klaus Mohrs; Elisabeth Perzborn; Friedel Seuter; Romanis Fruchtmann; Christian Kohlsdorfer


Archive | 1994

Heterocyclically substituted phenylacetic acid derivatives and their use in medicaments

Ulrich Dr. Müller; Klaus Mohrs; Jürgen Dr. Dressel; Rudolf Dr. Hanko; Walter Dr. Hübsch; Michael Matzke; Ulrich Niewohner; Siegfried Raddatz; Thomas Dr. Krämer; Matthias Dr. Müller-Gliemann; Hans-Peter Belleman; Martin Dr. Beuck; Stanislav Kazda; Stefan Wohlfeil

Researchain Logo
Decentralizing Knowledge